Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Metric	Value
Current Market Cap	$1.21B
Last Price	$10.46
52-Week High	$11.97
52-Week Low	$6.13

	A	B	C	D
1	Symbol	Price	Change	Volume
2	NVAX	$10.46	+13.57%	8.30M
3
4
5

Novavax Inc. (NVAX) Market Capitalization

Market Cap Data

Get Novavax Inc. Data in Excel

More NVAX Financial Data